Drug · Adc
Brentuximab Vedotin
CI-DRUG-00000718Explore in graph →CHEMBL1742994 Approved
Regulatory
Approvals (16)
Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.
- Source
- openFDA — Drugs@FDA applications and drug labels (SPL)
- Dataset
- Drugs@FDA via openFDA
- Version
- drugsfda-2026-09-11
- Retrieved
- Sep 14, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- regulatory
- License
- CC0 1.0 Universal (public domain; https://open.fda.gov/license/)
- Run
- ING-OPENFDA-20260914-000001
| Jurisdiction · authority | Cancer | Indication | Status | Approval date | Source |
|---|---|---|---|---|---|
| US FDA | — | Efficacy supplement 2025-02-11 (see label) | approved | Feb 11, 2025 | openfda |
| US FDA | — | Efficacy supplement 2023-06-14 (see label) | approved | Jun 14, 2023 | openfda |
| US FDA | — | Efficacy supplement 2022-11-10 (see label) | approved | Nov 10, 2022 | openfda |
| US FDA | — | Efficacy supplement 2018-11-16 (see label) | approved | Nov 16, 2018 | openfda |
| US |
Health Canada records are DIN-level: one row per marketed product (brand, strength, form). The Drug Product Database does not publish indications, so no cancer is stated for these rows, and a cancelled or dormant DIN is the status of that one product — not a withdrawal of the molecule.
Data updated 20 hours agoSource updated unknown
Derived
Development pipeline
Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.
| Scope | Stage | Max phase | Active | Recruiting | Phase 3 | Trials | Approvals | Jurisdictions | First approval | First trial |
|---|---|---|---|---|---|---|---|---|---|---|
| All cancers | Approved | Phase 4 | 44 | 19 | 19 | 161 | 16 | CA, EU, US | Aug 19, 2011 | 2004-09 |
| Hodgkin Lymphoma | Approved | Phase 4 | 26 | 10 | 12 | 87 | 4 | US | Aug 19, 2011 | 2006-04 |
| Non-Hodgkin Lymphoma | Approved | Phase 4 | 15 | 7 | 6 | 54 | 2 | EU, US | Aug 19, 2011 | 2006-08 |
| Leukemia | Phase2 | Phase 2 | 2 | 2 | 0 | 11 | 0 | — |
Curated evidence
Clinical evidence (0)
CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.
Data not yet available
Clinical trials
Trials with this intervention (167)
Most recently updated first, 50 per page.
- Source
- ClinicalTrials.gov
- Dataset
- ClinicalTrials.gov API v2 studies
- Retrieved
- Sep 30, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01896999 | Brentuximab Vedotin and Nivolumab With or Without Ipilimumab in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma | active not recruiting | Phase 1 / Phase 2 | 146 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2026 | clinicaltrials |
| NCT05675410 | A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab |